Clinical research of oxaliplatin in combination with HCPT, LV and 5-FU regimen for advanced gastric cancer

The objective of this study was to observe the curative effects and adverse reactions in the treatment of advanced gastric cancer with OHLF3 and HLFP regimen. Methods: In a non-randomized manner, 56 patients with advanced gastric cancer were divided into the treatment group (OHLF3) and control group (HLFP). OHLF3 regimen: OXA 130 mg/m2 iv d_1, HCPT 6 mg/m2 iv d_1-d_5 were given, LV 100 mg/m2 and 5-FU 500 mg/m2 iv d_2 to d_6. HLFP regimen: DDP 25 mg/m2 iv d_1-d_3 was given, HCPT 6 mg/m2 iv d_1-d_5, LV 100 mg/m2 and 5-FU 500 mg/m2 iv d_6-d_ 10 . Every 21 days was 1 cycle. Tumor assessments were done after 3 cycles. Results: the over all response rates in the treatment group (32 cases) and control group (24 cases) were 56.3 %(18/32) and 41.2 %(10/24) respectively. There was no significant difference (χ2=1.167, P=0.280). The side effects of both groups were neutropenia nausea, vomiting, stomatitis, diarrhea and neuritis. Conclusions: the side effects of LOHP plus HCPT, LV and 5-Fu were slight. The regimen appears to be very good for patients with advanced gastric cancer.